{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21", "items" : [{"_about" : "http://data.parliament.uk/resources/1092654", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092654/answer", "answerText" : {"_value" : "<p>To date, over 500,000 young people have taken part in the NCS programme. The most recently published evaluation has found that 82% of young people felt more positive about people from different backgrounds, and participants are more likely to use their time to help others after NCS<sup><sup>[1]<\/sup><\/sup>. Marketing is a key recruitment driver for NCS, ensuring that more young people across the country benefit from the programme.<\/p><p> <\/p><p>The brand refresh is one part of the overall marketing and creative services tender which includes communications planning, creative strategy, brand platform, experience, advertising campaign development, and content production. The £10m figure was stated in a NCS Trust procurement document as an upper limit over 4 years. The actual cost of the contract is likely to be around £1m per year, for 4 years of the contract.<\/p><p> <\/p><p>The NCS Trust is forecast to self-generate c. £3m income in the upcoming financial year. The brand refresh element of the marketing and creative services contract in question will be paid from those funds and we can confirm that no government funding will be spent on this element of the contract. The remainder of the contract will be funded by Government funding.<\/p><p> <\/p><p><sup><sup>[1]<\/sup><\/sup> This figure is based on the 2016 programme evaluation, which can be found <a href=\"https://www.gov.uk/government/publications/national-citizen-service-evaluation-report-2016\" target=\"_blank\">here<\/a>. The 2017 evaluation report is currently being finalised.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4513", "label" : {"_value" : "Biography information for Mims Davies"}
        }
        , "answeringMemberConstituency" : {"_value" : "Eastleigh"}
        , "answeringMemberPrinted" : {"_value" : "Mims Davies"}
        , "dateOfAnswer" : {"_value" : "2019-03-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-26T13:42:17.07Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "10"}
      , "answeringDeptShortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "answeringDeptSortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Voluntary Work: Young People"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Digital, Culture, Media and Sport, what the  source of funding is for the £10 million brand refresh for the National Citizen Service; and whether he can confirm that no government funding will be spent on this contract.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4436", "label" : {"_value" : "Biography information for Cat Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lancaster and Fleetwood"}
      , "tablingMemberPrinted" : [{"_value" : "Cat Smith"}
      ], "uin" : "235376"}
    , {"_about" : "http://data.parliament.uk/resources/1092655", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092655/answer", "answerText" : {"_value" : "<p>Hospital pharmacy aseptic services can be provided under either:<\/p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or<\/p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p><p> <\/p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.<\/p><p> <\/p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.<\/p><p> <\/p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.<\/p><p> <\/p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.<\/p><p> <\/p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department\u2019s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.<\/p><p><strong> <\/strong><\/p><p><strong> <\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gosport"}
        , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
        , "dateOfAnswer" : {"_value" : "2019-03-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "235305"}
        , {"_value" : "235306"}
        , {"_value" : "235307"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-28T16:18:41.557Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmacy: Safety"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department has taken to manage risks to safety in compounding facilities in (a) NHS organisations and (b) commercial aseptic pharmacies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
      ], "uin" : "235304"}
    , {"_about" : "http://data.parliament.uk/resources/1092656", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092656/answer", "answerText" : {"_value" : "<p>Hospital pharmacy aseptic services can be provided under either:<\/p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or<\/p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p><p> <\/p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.<\/p><p> <\/p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.<\/p><p> <\/p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.<\/p><p> <\/p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.<\/p><p> <\/p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department\u2019s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.<\/p><p><strong> <\/strong><\/p><p><strong> <\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gosport"}
        , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
        , "dateOfAnswer" : {"_value" : "2019-03-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "235304"}
        , {"_value" : "235306"}
        , {"_value" : "235307"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-28T16:18:41.603Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmacy: Capital Investment"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how much capital funding has been spent on (a) pharmacy services, (b) aseptic pharmacy services and (c) compounding pharmacy services in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
      ], "uin" : "235305"}
    , {"_about" : "http://data.parliament.uk/resources/1092657", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092657/answer", "answerText" : {"_value" : "<p>Hospital pharmacy aseptic services can be provided under either:<\/p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or<\/p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p><p> <\/p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.<\/p><p> <\/p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.<\/p><p> <\/p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.<\/p><p> <\/p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.<\/p><p> <\/p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department\u2019s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.<\/p><p><strong> <\/strong><\/p><p><strong> <\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gosport"}
        , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
        , "dateOfAnswer" : {"_value" : "2019-03-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "235304"}
        , {"_value" : "235305"}
        , {"_value" : "235307"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-28T16:18:41.647Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmacy: Staff"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of workforce pressures in compounding pharmacies operated by (a) NHS organisations and (b) non-NHS organisations; and whether the pharmacy workforce will be included in the forthcoming NHS workforce plan.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
      ], "uin" : "235306"}
    , {"_about" : "http://data.parliament.uk/resources/1092658", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092658/answer", "answerText" : {"_value" : "<p>Hospital pharmacy aseptic services can be provided under either:<\/p><p>- a specific exemption for pharmacists within medicine legislation (derived from section 10 of the Medicines Act 1968); or<\/p><p>- a specials manufacturing licence from the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p><p> <\/p><p>Either approach requires services to meet the standards set by the MHRA within nationally recognised Good Manufacturing Practice. Licensed facilities are inspected by the MHRA and section 10 facilities are audited by regional quality assurance specialists under an Executive Letter, describing the arrangements for auditing unlicensed National Health Service aseptic units. The outcomes and risk ratings are reviewed through the NHS England Specialist Pharmacy Service.<\/p><p> <\/p><p>Commercial aseptic pharmacies must hold a specials manufacturing licence from the MHRA to supply compounded aseptic products to the NHS. The MHRA has its own inspection team who visit and review licensed facilities including both NHS and commercial. The MHRA has regulatory enforcement powers to close, restrict or require improvement in these licensed facilities.<\/p><p> <\/p><p>Capital spend to support individual pharmacy, aseptic or other NHS compounding services has historically been locally determined or has been part of wider whole hospital developments and, as such, there is no central repository of such spend.<\/p><p> <\/p><p>NHS Improvement has, through the initial work of reviewing NHS-provided aseptic services, identified a range of challenges linked to such services, including workforce. The next stage of this work will focus on workforce provision within the wider strategic review. This work does not include non-NHS organisations. Health Education England is undertaking a review that, linked with the NHS Improvement strategic service review, will identify the pharmacy technical services workforce issues across all grades and workforce groups.<\/p><p> <\/p><p>Aseptically compounded products are prepared from medicines that, in line with all medicines, are covered by the Department\u2019s European Union exit planning process and products would all be included within the six-week additional stockpiling being managed through pharmaceutical suppliers.<\/p><p><strong> <\/strong><\/p><p><strong> <\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
        }
        , "answeringMemberConstituency" : {"_value" : "Gosport"}
        , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
        , "dateOfAnswer" : {"_value" : "2019-03-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "235304"}
        , {"_value" : "235305"}
        , {"_value" : "235306"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-28T16:18:41.68Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmacy"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect on aseptic compounding pharmacies operated by (a) NHS organisations and (b) non-NHS organisations of the UK leaving the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
      ], "uin" : "235307"}
    , {"_about" : "http://data.parliament.uk/resources/1092659", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092659/answer", "answerText" : {"_value" : "<p>The project to develop and test the feasibility of new models that pay companies for antimicrobials based primarily on a heath technology assessment of their value to the National Health Service as opposed to the volumes used, and to share the learning with international stakeholders, is expected to be established by July this year.<\/p><p> <\/p><p>The NHS Long Term Plan, published in January this year, makes the commitment to implement the human health aspects of \u2018Tackling Antimicrobial Resistance (2019-2024): the UK\u2019s five-year national action plan\u2019. The project will be led by a central project team resourced by the National Institute for Health and Care Excellence and NHS England and the National Institute for Health Research Policy Research Programme is considering research to support the process.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2019-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-29T14:35:37.427Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Tackling antimicrobial resistance 2019\u20132024: The UK\u2019s five-year national action plan, published on 24 January 2019, what plans he has to fund the (a) design and (b) testing of a new economic model for antibiotics.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cambridge"}
      , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
      ], "uin" : "235308"}
    , {"_about" : "http://data.parliament.uk/resources/1092660", "AnsweringBody" : [{"_value" : "Department for Transport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092660/answer", "answerText" : {"_value" : "<p>The Department made clear, in its 2018 response to the Cycling and Walking Investment Strategy Safety Review, that local councils should invest around 15 per cent of their local transport infrastructure funding on safe and efficient cycling and walking infrastructure. The Department continues to encourage local authorities to make use of the Transforming Cities Fund and other relevant national funding streams to support cycling and walking schemes and engages regularly with them in the development of their LCWIPs (Local Cycling and Walking Infrastructure Plans). Departmental officials have had discussions from time to time with representatives from the Local Government Association to discuss local authorities\u2019 support for cycling and walking.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3991", "label" : {"_value" : "Biography information for Jesse Norman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Hereford and South Herefordshire"}
        , "answeringMemberPrinted" : {"_value" : "Jesse Norman"}
        , "dateOfAnswer" : {"_value" : "2019-03-25", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-25T15:57:25.62Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "27"}
      , "answeringDeptShortName" : {"_value" : "Transport"}
      , "answeringDeptSortName" : {"_value" : "Transport"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cycling and Walking"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Transport, what discussions he has had with the Local Government Association on encouraging councils to use City Region Deals to increase access to cycling and walking routes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "235309"}
    , {"_about" : "http://data.parliament.uk/resources/1092661", "AnsweringBody" : [{"_value" : "Department for Transport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092661/answer", "answerText" : {"_value" : "<p>The Government recognises the importance of public transport in reducing social isolation, particularly in rural areas. Where there is not enough demand for a bus route to be commercially viable, all local authorities in England have powers to subsidise bus services. The Department provides £43 million per year to local authorities to support this. As part of the 2018-19 local government finance settlement, the Ministry of Housing, Communities and Local Government responded to a number of councils\u2019 concerns over rural services funding by increasing the Rural Services Delivery Grant to £81 million. The 2019-20 settlement increased the Grant to the same level. This recognises the extra costs of providing services in rural communities. It is up to local government officials to decide how this funding is distributed.<\/p><p><strong> <\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4460", "label" : {"_value" : "Biography information for Ms Nusrat Ghani"}
        }
        , "answeringMemberConstituency" : {"_value" : "Wealden"}
        , "answeringMemberPrinted" : {"_value" : "Ms Nusrat Ghani"}
        , "dateOfAnswer" : {"_value" : "2019-03-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-29T13:42:34.9Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "27"}
      , "answeringDeptShortName" : {"_value" : "Transport"}
      , "answeringDeptSortName" : {"_value" : "Transport"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Bus Services: Rural Areas"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Transport, what steps he is taking to secure less profitable rural bus routes and prevent an increase in rural isolation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "235310"}
    , {"_about" : "http://data.parliament.uk/resources/1092662", "AnsweringBody" : [{"_value" : "Department for Transport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092662/answer", "answerText" : {"_value" : "<p>The Government is supportive of all airports, including Belfast and Cardiff, in creating new international connections. The Government believes that air passengers are best served by a competitive commercial airline market. It is for airlines to determine which airports they operate, based on their own assessment of costs and passenger demand.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3991", "label" : {"_value" : "Biography information for Jesse Norman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Hereford and South Herefordshire"}
        , "answeringMemberPrinted" : {"_value" : "Jesse Norman"}
        , "dateOfAnswer" : {"_value" : "2019-03-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-26T16:43:10.73Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "27"}
      , "answeringDeptShortName" : {"_value" : "Transport"}
      , "answeringDeptSortName" : {"_value" : "Transport"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Air Routes"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Transport, what steps he is taking to increase the number of global routes to smaller airports in Belfast and Cardiff and other essential hubs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "235311"}
    , {"_about" : "http://data.parliament.uk/resources/1092663", "AnsweringBody" : [{"_value" : "Treasury"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092663/answer", "answerText" : {"_value" : "<p>The UK has engaged with a wide range of stakeholders, including all EU Member States and many of the jurisdictions being assessed, as part of the process for agreeing the EU list of non-cooperative jurisdictions for tax purposes.<\/p><p> <\/p><p>Bermuda is a fiscally sovereign jurisdiction, and has been liaising directly with the EU institutions on this issue.<\/p><p> <\/p><p>The UK supports the list and has been active in discussions, ensuring the process is fair an objective across all jurisdictions.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3935", "label" : {"_value" : "Biography information for Mel Stride"}
        }
        , "answeringMemberConstituency" : {"_value" : "Central Devon"}
        , "answeringMemberPrinted" : {"_value" : "Mel Stride"}
        , "dateOfAnswer" : {"_value" : "2019-03-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-03-26T13:48:00.347Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "14"}
      , "answeringDeptShortName" : {"_value" : "Treasury"}
      , "answeringDeptSortName" : {"_value" : "Treasury"}
      , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Taxation: Bermuda"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Chancellor of the Exchequer, what representations his Department has made to the EU on behalf of Bermuda on its inclusion on the EU list of non-cooperative jurisdictions for tax purposes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4657", "label" : {"_value" : "Biography information for Anneliese Dodds"}
      }
      , "tablingMemberConstituency" : {"_value" : "Oxford East"}
      , "tablingMemberPrinted" : [{"_value" : "Anneliese Dodds"}
      ], "uin" : "235377"}
    ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&houseId=1&min-ddpCreated=2019-03-21T18%3A16%3A37.677Z&dateTabled=2019-03-21", "page" : 0, "startIndex" : 1, "totalResults" : 112, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}